Diego Rey co-founded GeneWEAVE in 2010 during his PhD studies at Cornell University. GeneWEAVE went on to commercialize a platform technology that enables the development of in vitro diagnostics for detecting bacteria and their antimicrobial susceptibility without the need for sample preparation. From 2010-2015 Diego served at GeneWEAVE's Chief Technology Officer during which time the company raised $25MM in venture capital investment and grew to 50 employees. In August 2015, Roche acquired GeneWEAVE for up to $425MM. Diego currently serves as the Head of Research for GeneWEAVE, a division of Roche Molecular Systems, Inc. where he continues to develop simple to use and cost effective diagnostics with the goal of reducing infections caused by multi drug resistant organisms worldwide.
We are glad to announce that this event will be a Joint event with B2DG and EPPIC. Given the limited seating at Wilson Sonsini, we strongly suggest you register early. If the last event is representative, there will likely be no walk-ins accepted.
Multi-drug resistant organisms (MDROs) threaten modern medicine’s progress by making common infections fatal and dramatically increasing the risk of complications for many medical procedures such as surgery, transplants, and chemotherapy. To solve this problem a global call has been issued to develop new diagnostics that detect MDROs and measure antibiotic effectiveness fast enough to make time-critical clinical decisions. GeneWEAVE is using Smarticles(TM) technology to develop fast, simple, and smart diagnostics to aid healthcare providers in the fight against drug-resistant bacteria by enabling impactful surveillance programs, early therapy guidance, and successful antibiotic stewardship. This talk describes the Smarticles technology and tells the story behind GeneWEAVE.